Cardiology
Latest news
1101 articles · 20 / page
Is Indefinite Heart Failure Therapy Necessary After AF Rhythm Control? Insights from the WITHDRAW-AF Trial
The WITHDRAW-AF trial suggests that heart failure therapy can be safely withdrawn in patients with atrial fibrillation-mediated cardiomyopathy who achieve rhythm control and ejection fraction normalization, showing no significant decline in
Targeted Education Enhances Rhythm Control Adherence in Atrial Fibrillation but Faces Limits in Stroke Prevention: Insights from STEEER-AF
The STEEER-AF cluster-randomized trial reveals that structured professional education significantly boosts adherence to complex rhythm control guidelines in atrial fibrillation, though it shows no significant impact on stroke prevention whe
Colchicine May Curb the Expansion of Pro-Inflammatory Clonal Hematopoiesis: Insights From the LoDoCo2 Substudy
A substudy of the LoDoCo2 trial suggests that low-dose colchicine may attenuate the expansion of specific clonal hematopoiesis driver mutations, particularly TET2, offering a potential mechanism for reducing cardiovascular risk by slowing t
Ketone Esters in HFpEF: Metabolic Reprogramming and Hemodynamic Gains Fail to Translate into Improved Exercise Capacity
The KETO-HFpEF trial demonstrates that while acute ketone ester supplementation effectively induces ketosis and improves resting hemodynamics, it fails to improve peak oxygen consumption or exercise endurance in patients with heart failure
Mavacamten Redefines Long-Term Outcomes in Obstructive Hypertrophic Cardiomyopathy: 128-Week Results From the VALOR-HCM Trial
The 128-week follow-up of the VALOR-HCM trial demonstrates that mavacamten provides sustained relief from LVOT obstruction, promotes favorable cardiac remodeling, and significantly reduces the need for invasive septal reduction therapy in p
Complete Revascularization Benefits Older MI Patients Regardless of Renal Function: Insights from the FIRE Trial
A sub-analysis of the FIRE trial demonstrates that physiology-guided complete revascularization significantly reduces major adverse cardiovascular events in patients aged 75 and older, irrespective of baseline kidney function, without incre
Validating the 0.80 FFR Threshold: Long-Term Outcomes from the NOTION-3 Trial in TAVR Patients
The NOTION-3 trial demonstrates that FFR-guided revascularization significantly reduces cardiovascular risks in TAVR patients with coronary artery disease, validating the 0.80 threshold for clinical decision-making.
Ticagrelor vs. Twice-Daily Clopidogrel in STEMI: Insights from the TADCLOT Trial
The TADCLOT trial compared ticagrelor to twice-daily clopidogrel in 2,201 STEMI patients post-PCI. While ticagrelor showed no 30-day superiority in MACE reduction, it demonstrated a significant benefit within the first two weeks with compar
Moving Beyond the 12-Month Default: Personalized DAPT Duration Proven Superior in the PARTHENOPE Trial
The PARTHENOPE randomized trial demonstrates that personalizing DAPT duration (3 to 24 months) based on individual risk scores significantly reduces net adverse clinical events compared to standard 12-month therapy, primarily by lowering is
Echocardiographic Remodeling and Atrial Dynamics with Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Insights from the ODYSSEY-HCM Trial
This exploratory analysis of the ODYSSEY-HCM trial demonstrates that mavacamten induces modest regression of left ventricular hypertrophy and improves diastolic and left atrial function in nonobstructive HCM, despite a 21.5% incidence of re
Vericiguat in Compensated HFrEF: Navigating the Complex Results of the VICTOR Trial and the Burden of Outpatient Worsening
The VICTOR trial evaluated vericiguat in stable HFrEF outpatients. While the primary endpoint was not met, exploratory analyses revealed significant mortality reductions and highlighted the prognostic importance of outpatient heart failure
Aficamten Superior to Metoprolol in Redefining the Structural and Hemodynamic Landscape of Obstructive HCM
The MAPLE-HCM trial reveals that aficamten significantly outperforms metoprolol in reducing LVOT gradients and promoting favorable cardiac remodeling in patients with symptomatic obstructive HCM, signaling a potential shift in first-line th
Long-Term ICD Benefits in Nonischemic HFrEF: Why Patient Age and Mode of Death Dictate Clinical Strategy
The extended 13.2-year follow-up of the DANISH trial demonstrates that while primary prevention ICDs do not reduce all-cause mortality in nonischemic HFrEF overall, they significantly lower sudden cardiovascular death risk, particularly in
Novel MicroNet-Covered Stent Sets New Safety Standard for High-Risk Carotid Artery Stenting: Insights from the C-GUARDIANS Trial
The C-GUARDIANS trial reveals that the CGuard MicroNet-covered stent significantly reduces embolic risks in high-risk carotid artery stenting, achieving a remarkably low 30-day DSMI rate of 0.95% and sustained neuroprotection through one ye
Pioneer Valve Demonstrates Mid-Term Efficacy for Pure Aortic Regurgitation in Multicenter Trial
The prospective Pioneer Trial demonstrates that a novel self-expanding TAVR device achieves 99.1% technical success and low mortality (2.7%) at one year for high-risk patients with pure aortic regurgitation, providing a safe, hemodynamicall
Precision Targeting of the Sarcomere: Danicamtiv Shows Genotype-Specific Efficacy in Dilated Cardiomyopathy
A Phase 2 trial demonstrates that danicamtiv, a novel cardiac myosin agonist, significantly improves left ventricular function in patients with genetic forms of dilated cardiomyopathy, particularly those with MYH7 and TTN variants, signalin
Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF
A prespecified analysis of the FINEARTS-HF trial demonstrates that the mineralocorticoid receptor antagonist finerenone consistently reduces cardiovascular death and heart failure events in patients with HFmrEF/HFpEF, regardless of baseline
Finerenone Provides Robust Protection Against Heart Failure Events Regardless of Baseline NYHA Functional Class
A prespecified analysis of the FINEARTS-HF trial confirms that finerenone reduces cardiovascular death and heart failure events in patients with HFmrEF and HFpEF across all symptomatic stages, offering the greatest absolute benefit to those
Sex-Specific Phenotypes and the Evolving Landscape of Aldose Reductase Inhibition in Diabetic Cardiomyopathy: Insights from ARISE-HF
This analysis of the Phase 3 ARISE-HF trial explores sex differences in diabetic cardiomyopathy (DbCM) and the efficacy of AT-001. While women presented with worse exercise capacity and health status at baseline, the novel aldose reductase
Intensive Blood Pressure Control to <120 mmHg: Holistic Benefits Across Frailty, Quality of Life, and Microvascular Health in the ESPRIT Trial
The ESPRIT trial reveals that targeting systolic blood pressure below 120 mmHg significantly reduces cardiovascular events across diverse populations, including frail patients and those with diabetes, while uniquely improving retinal microv
Browse by specialty
Open language-specific specialty feeds and department pages.